DCRI Co-Hosts Youth Tobacco Cessation Workshop at FDA

June 7, 2019 - The event drew nearly 900 registrants and discussed tobacco-cessation therapies that have been successful in youth populations, as well as gaps in knowledge surrounding e-cigarettes.

The DCRI and Institute for Advanced Clinical Trials for Children (I-ACT) co-hosted the Youth Tobacco Cessation: Strategies and Treatments Workshop on May 15 at the U.S. Food and Drug Administration (FDA) Headquarters in Silver Spring, Maryland.

Nearly 900 people registered to learn about existing experience with tobacco-cessation therapies in youth, the gaps in knowledge surrounding e-cigarettes, and expert recommendations for how to fill those gaps. The workshop speakers represented government agencies, research groups, youth advocacy groups, and the pharmaceutical industry. The FDA Acting Commissioner, Norman “Ned” Sharpless, MD, addressed the workshop participants.

“There is no dispute that years of progress to combat youth use of tobacco to prevent a lifetime of addiction to nicotine is now threatened by an epidemic of e-cigarette use among children,” Sharpless said. “These products are exposing a whole new generation of kids to nicotine and the possibility of addiction.”

Workshop participants will use lessons learned during the workshop to help guide future use of resources to address youth tobacco cessation.

The topics addressed at the meeting included (slides can be found at the links below):

E-Cigarette Prevention in Youth: New Challenges, New Strategies

  • Brian King, PhD, MPH, Office on Smoking and Health, US Centers for Disease Control and Prevention - click to view slides
  • Kathleen Crosby, MPH, Center for Tobacco Products, FDA - click to view slides

The Science of Addiction in Adolescents

What Can We Learn from the Blueprint for Action?

Experience with Cessation Therapies in Adolescents

Addressing the Gaps: Where Should Treatment Efforts Be Focused?

The FDA, I-ACT and the DCRI published a meeting summary in August 2019.